We are developing therapies that target muscle tissue with unprecedented precision to restore muscle health. The company’s FORCE™ platform can deliver oligonucleotides and other molecules to skeletal, cardiac and smooth muscle to treat a range of serious muscle diseases. In addition to Dyne’s initial focus on myotonic dystrophy type 1 (DM1), we are advancing additional programs in Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD).
We have designed a therapeutic molecule by linking an antibody to an oligonucleotide.
The receptor is highly expressed on muscle cells. By engaging the receptor, the antibody brings the oligonucleotide to the primary site of disease and facilitates delivery into the muscle cells.
Once inside the cell, the oligonucleotide binds with the RNA that is driving disease progression.
Disease-causing RNA is degraded.
This highly targeted approach is designed to promote muscle health.